Calcipotriol/betamethasone for the treatment of psoriasis: efficacy, safety, and patient acceptability

Christina RogalskiMedical Business Development, edia.con gemeinnützige GmbH, Leipzig, Saxony, GermanyBackground: One of the advances in the treatment of plaque-type psoriasis is combined local therapy with calcipotriol and betamethasone. To provide both ingredients in a two-compound product...

Full description

Bibliographic Details
Main Author: Rogalski C
Format: Article
Language:English
Published: Dove Medical Press 2015-06-01
Series:Psoriasis: Targets and Therapy
Online Access:http://www.dovepress.com/calcipotriolbetamethasone-for-the-treatment-of-psoriasis-efficacy-safe-peer-reviewed-article-PTT
_version_ 1818751168252215296
author Rogalski C
author_facet Rogalski C
author_sort Rogalski C
collection DOAJ
description Christina RogalskiMedical Business Development, edia.con gemeinnützige GmbH, Leipzig, Saxony, GermanyBackground: One of the advances in the treatment of plaque-type psoriasis is combined local therapy with calcipotriol and betamethasone. To provide both ingredients in a two-compound product, efforts have been made to unite calcipotriol and betamethasone because they are usually inactivated when present in the same formulation. This aspect was resolved when carefully designed vehicle components were invented (gel and ointment). This article reviews the efficacy, safety, and patient acceptability of calcipotriol/betamethasone dipropionate.Methods: A literature search of all articles published until February 2015 was performed, including the largest medical databases. The search strategy for evaluating the main topics of this review – efficacy, safety, and patient acceptability – was defined before checking the publications.Results: Seventy references were found and checked for relevance. For efficacy, the proportion of patients whose psoriasis improved was always significantly higher in the two-compound group compared to the group treated with the individual substances. In the context of safety, the fixed combination was generally associated with a lower risk of adverse events. In terms of patient acceptability, the fixed combination led to a significant improvement in quality of life. The two-compound product was more convenient to handle and time saving compared to former treatments.Conclusion: Calcipotriol/betamethasone dipropionate in a fixed combination is an effective and well-tolerated medication in mild-to-moderate psoriasis of body and scalp and, in addition, is an evidence-based treatment modality.Keywords: psoriasis, calcipotriol/betamethasone, safety, efficacy, fixed combination, two-compound medication
first_indexed 2024-12-18T04:31:17Z
format Article
id doaj.art-e8817301c9ba4248b8262399ef62c6be
institution Directory Open Access Journal
issn 2230-326X
language English
last_indexed 2024-12-18T04:31:17Z
publishDate 2015-06-01
publisher Dove Medical Press
record_format Article
series Psoriasis: Targets and Therapy
spelling doaj.art-e8817301c9ba4248b8262399ef62c6be2022-12-21T21:20:59ZengDove Medical PressPsoriasis: Targets and Therapy2230-326X2015-06-012015default9710722075Calcipotriol/betamethasone for the treatment of psoriasis: efficacy, safety, and patient acceptabilityRogalski CChristina RogalskiMedical Business Development, edia.con gemeinnützige GmbH, Leipzig, Saxony, GermanyBackground: One of the advances in the treatment of plaque-type psoriasis is combined local therapy with calcipotriol and betamethasone. To provide both ingredients in a two-compound product, efforts have been made to unite calcipotriol and betamethasone because they are usually inactivated when present in the same formulation. This aspect was resolved when carefully designed vehicle components were invented (gel and ointment). This article reviews the efficacy, safety, and patient acceptability of calcipotriol/betamethasone dipropionate.Methods: A literature search of all articles published until February 2015 was performed, including the largest medical databases. The search strategy for evaluating the main topics of this review – efficacy, safety, and patient acceptability – was defined before checking the publications.Results: Seventy references were found and checked for relevance. For efficacy, the proportion of patients whose psoriasis improved was always significantly higher in the two-compound group compared to the group treated with the individual substances. In the context of safety, the fixed combination was generally associated with a lower risk of adverse events. In terms of patient acceptability, the fixed combination led to a significant improvement in quality of life. The two-compound product was more convenient to handle and time saving compared to former treatments.Conclusion: Calcipotriol/betamethasone dipropionate in a fixed combination is an effective and well-tolerated medication in mild-to-moderate psoriasis of body and scalp and, in addition, is an evidence-based treatment modality.Keywords: psoriasis, calcipotriol/betamethasone, safety, efficacy, fixed combination, two-compound medicationhttp://www.dovepress.com/calcipotriolbetamethasone-for-the-treatment-of-psoriasis-efficacy-safe-peer-reviewed-article-PTT
spellingShingle Rogalski C
Calcipotriol/betamethasone for the treatment of psoriasis: efficacy, safety, and patient acceptability
Psoriasis: Targets and Therapy
title Calcipotriol/betamethasone for the treatment of psoriasis: efficacy, safety, and patient acceptability
title_full Calcipotriol/betamethasone for the treatment of psoriasis: efficacy, safety, and patient acceptability
title_fullStr Calcipotriol/betamethasone for the treatment of psoriasis: efficacy, safety, and patient acceptability
title_full_unstemmed Calcipotriol/betamethasone for the treatment of psoriasis: efficacy, safety, and patient acceptability
title_short Calcipotriol/betamethasone for the treatment of psoriasis: efficacy, safety, and patient acceptability
title_sort calcipotriol betamethasone for the treatment of psoriasis efficacy safety and patient acceptability
url http://www.dovepress.com/calcipotriolbetamethasone-for-the-treatment-of-psoriasis-efficacy-safe-peer-reviewed-article-PTT
work_keys_str_mv AT rogalskic calcipotriolbetamethasoneforthetreatmentofpsoriasisefficacysafetyandpatientacceptability